E-LIB Suche - Ergebnisse für: Berton-Rigaud, Dominique - Sprache DE

Sortierung: Relevanz

Sortierung: Jahr

1

Spatial profiling of ovarian carcinoma and tumor microenvir..:

Yaniz-Galende, Elisa ; Zeng, Qinghe ; Grau-Bejar, Juan Francisco...
Clinical Cancer Research. , 2024

Link: https://doi.org/10.1158/..

2

Dissecting the Origin of Heterogeneity in Uterine and Ovari..:

Sertier, Anne-Sophie ; Ferrari, Anthony ; Pommier, Roxane M....
Cancer Research Communications. 3 (2023) 5 - p. 830-841 , 2023

Link: https://doi.org/10.1158/..

3

Surgical Implications of Advanced Low-Grade Serous Ovarian ..:

Bonsang-Kitzis, Hélène ; Panchbhaya, Nabilah ; Bats, Anne-Sophie...
Cancers. 14 (2022) 9 - p. 2345 , 2022

Link: https://doi.org/10.3390/..

4

Chronic fatigue, quality of life and long-term side-effects..:

Gernier, François ; Ahmed-Lecheheb, Djihane ; Pautier, Patricia...
BMC Cancer. 21 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

5

Comparative analysis of predictive values of the kinetics o..:

Robelin, Patrick ; Tod, Michel ; Colomban, Olivier...
Gynecologic Oncology. 159 (2020) 1 - p. 256-263 , 2020

Link: https://doi.org/10.1016/..

6

Pembrolizumab in patients with programmed death ligand 1–po..:

Varga, Andrea ; Piha-Paul, Sarina ; Ott, Patrick A....
Gynecologic Oncology. 152 (2019) 2 - p. 243-250 , 2019

Link: https://doi.org/10.1016/..

7

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carbo..:

Romeo, Clémence ; Joly, Florence ; Ray-Coquard, Isabelle...
Gynecologic Oncology. 152 (2019) 1 - p. 68-75 , 2019

Link: https://doi.org/10.1016/..

8

A phase 1 study of lirilumab (antibody against killer immun..:

Vey, Norbert ; Karlin, Lionel ; Sadot-Lebouvier, Sophie...
Oncotarget. 9 (2018) 25 - p. 17675-17688 , 2018

Link: https://doi.org/10.18632..

9

Phase I study of onapristone, a type I antiprogestin, in fe..:

Cottu, Paul H. ; Bonneterre, Jacques ; Varga, Andrea...
PLOS ONE. 13 (2018) 10 - p. e0204973 , 2018

Link: https://doi.org/10.1371/..

10

Measuring what matters MOST: validation of the Measure of O..:

King, Madeleine T. ; Stockler, Martin R. ; O'Connell, Rachel L....
Quality of Life Research. 27 (2018) 1 - p. 59-74 , 2018

Link: https://www.jstor.org/st..

11

Validation of the modified Glasgow Prognostic Score (mGPS) ..:

Roncolato, Felicia T. ; Berton-Rigaud, Dominique ; O'Connell, Rachel...
Gynecologic Oncology. 148 (2018) 1 - p. 36-41 , 2018

Link: https://doi.org/10.1016/..

12

Reducing Uncertainty: Predictors of Stopping Chemotherapy E..:

Roncolato, Felicia T. ; Joly, Florence ; O'Connell, Rachel...
The Oncologist. 22 (2017) 9 - p. 1117-1124 , 2017

Link: https://doi.org/10.1634/..

13

Measuring what matters MOST: validation of the Measure of O..:

for the GCIG Symptom Benefit group ; King, Madeleine T. ; Stockler, Martin R....
Quality of Life Research. 27 (2017) 1 - p. 59-74 , 2017

Link: https://doi.org/10.1007/..

14

BRCA1/2 mutations associated with progression-free survival..:

Harter, Philipp ; Johnson, Toby ; Berton-Rigaud, Dominique...
Gynecologic Oncology. 140 (2016) 3 - p. 443-449 , 2016

Link: https://doi.org/10.1016/..

15

Communicating BRCA research results to patients enrolled in..:

Pulford, David J. ; Harter, Philipp ; Floquet, Anne...
BMC Medical Ethics. 17 (2016) 1 - p. , 2016

Link: https://doi.org/10.1186/..

1-15